| Literature DB >> 35887251 |
Abstract
In traditional medicine, different parts of plants, including fruits, have been used for their anti-inflammatory and anti-oxidative properties. Plant-based foods, such as fruits, seeds and vegetables, are used for therapeutic purposes due to the presence of flavonoid compounds. Proanthocyanidins (PCs) and anthocyanins (ACNs) are the major distributed flavonoid pigments in plants, which have therapeutic potential against certain chronic diseases. PCs and ACNs derived from plant-based foods and/or medicinal plants at different nontoxic concentrations have shown anti-non-small cell lung cancer (NSCLC) activity in vitro/in vivo models through inhibiting proliferation, invasion/migration, metastasis and angiogenesis and by activating apoptosis/autophagy-related mechanisms. However, the potential mechanisms by which these compounds exert efficacy against nicotine-induced NSCLC are not fully understood. Thus, this review aims to gain insights into the mechanisms of action and therapeutic potential of PCs and ACNs in nicotine-induced NSCLC.Entities:
Keywords: NSCLC; anthocyanins; flavonoids; nicotine; proanthocyanidins
Mesh:
Substances:
Year: 2022 PMID: 35887251 PMCID: PMC9316101 DOI: 10.3390/ijms23147905
Source DB: PubMed Journal: Int J Mol Sci ISSN: 1422-0067 Impact factor: 6.208
Figure 1Mechanisms for nicotine in the development of NSCLC.
The molecular mechanisms of PCs in nicotine-induced NSCLC treatment.
| Study Type | NSCLC Cell Type | Extract/Compound | Concentrations | Activity | Mechanisms of Action | Reference |
|---|---|---|---|---|---|---|
| In vitro | DMS114 | Cranberry presscake | 200–300 µmol/L | Anti-proliferative, apoptosis | NA | [ |
| In vitro | H460 | Cranberry ( | 20–80 µg/mL | Anti-proliferative | MMP2, MMP9↓ | [ |
| In vitro | H460 | Cranberry ( | 50 µg/mL | Apoptosis, cell cycle arrest | P21, P73, PARP, cytochrome | [ |
| In vitro/vivo | A549 | Grape seed | 100 µg/mL (in vitro) | Inhibition of tumor angiogenesis | MMP2↓ | [ |
| In vitro/vivo | A549, H1299 | Grape seed | 60, 80 µg/mL (in vitro) | Anti-proliferative, anti-angiogenic, apoptosis | PCNA↓ | [ |
| In vitro/vivo | H157, H226, H460, H1299, A549 | Grape seed | 20, 40, and 60 µg/mL (in vitro) | Anti-proliferative, apoptosis | COX-2, PGI-2↓ | [ |
| In vitro | A549, H1299 | Grape seed | 10, 20, 40, and 60 µg/mL | Anti-migration | NO, L-NAME, MAPK, ERK1/2↓ | [ |
| In vitro | A549 | Grape seed | 6 µg/mL | Anti-proliferative, apoptosis | caspase 3, PTGIS/PGI2↑ | [ |
| In vitro | A549, H1299, H460 | Grape seed | 20 and 40 µg/mL | Anti-migration | E-cadherin, NOX, p22/p47(phox)↓ | [ |
| In vitro/vivo | A549, H1299 | Grape seed | 20, 40, and 60 µg/mL (in vitro) | Apoptosis | G1arrest, Bax, caspases-3/9, Cdki, PARP↑ | [ |
| In vitro/vivo | A549 | Grape seed | 45 µg/mL (in vitro) | Anti-proliferative, anti-invasive | CDKN1A, p21↑, | [ |
| In vitro | A549 | Cinnamomi Cortex | 2.5 µg/mL | Inhibition of cell viability and proliferation | Nrf2↓ | [ |
| In vitro | A549 | Cinnamomi Cortex | 10 µg/mL | Inhibition of cell proliferation | Nrf2, IGF-1R↓ | [ |
| In vitro | A549 | Cinnamomi Cortex | 12.5, 25, 50, and 100 µg/mL | Anti-metastatic | TGF-β, snail, E-cadherin, smad2↓ | [ |
| In vitro | A549 | PCs | ≥100 mg/L | Inhibition of cell viability | ROS, MDA, Nrf2↓ | [ |
| In vitro | A549 | PCs | 12.5, 25, 50, 100, and 200 µM | Inhibition of cell viability and proliferation, apoptosis, cell cycle arrest | N-cadherin, vimentin, Bcl-2, MMP2/9, JAK2/STAT3↓, | [ |
| In vitro | A549 | Green tea leaf | 1, 5, 10, 20 µM | Anti-proliferative, apoptosis, cell cycle arrest | P21, P53, Fas/sFasL, Fas/APO-1↑ | [ |
| In vitro | A549 |
| 0.5, 2.5, 5, and 10 µM | Anti-proliferative, apoptosis, cell cycle arrest | Fas/APO-1, P21/WAF1, P53, Fas/sFasL↑ | [ |
| In vitro | A549, H460 |
| 125, 150, and 175 µM | Autophagy | Akt/mTOR↓ | [ |
(↑) increase; (↓) decrease; NA: not mentioned.
The molecular mechanisms of ACNs in nicotine-induced NSCLC treatment.
| Study Type | NSCLC Cell Type | Extract/Compound | Concentrations | Activity | Mechanisms of Action | Reference |
|---|---|---|---|---|---|---|
| In vitro | A549 |
| 200 µg/mL | Anti-proliferative, anti-invasive, anti-angiogenic, anti-migration | MMP2/9, cyclin D1, C-myc, COX-2, VEGF↓ | [ |
| In vitro | A549 | 25, 50, and 100 µM | Anti-migration, anti-invasive | MMP2, c-Jun, C-fos, NF-kB↓ | [ | |
| In vitro | A549, H1299 | Cyanidin-3-glucoside | 5, 10, 20, 40, and 80 µM | Anti-proliferative, anti-migration, anti-invasive, apoptosis | TP53I3 andPI3K/Akt/mTOR↓ | [ |
| In vitro/vivo | A549, H441, SK-MES-1 | Delphinidin | 5–100 µM (in vitro) | Inhibition of tumor growth, anti-proliferative, anti-angiogenic, apoptosis | EGFR, Bcl-2, PCNA, cyclin D1, VEGFA, Akt/PI3K/MAPK↓ | [ |
| In vitro/vivo | A549 | Delphinidin | 10, 20, and 40 µM (in vitro) | Anti-angiogenic | EGF, CoCl2, HIF-1α, ERK, VEGF mRNA, Akt/mTOR/PI3K/p70S6K↓ | [ |
| In vitro/vivo | A549, H1299 | Bilberry and blueberry | 3.125–12.5 µM (in vitro) | Anti-metastatic, anti-invasive, apoptosis, cell cyclearrest | TNFα-induced NF-kB, Notch, Wnt/β-catenin, cyclinD1/B1, VEGF, p-ERK, bcl-2, MMP9 ↓ | [ |
| In vitro | A549 | 2.5, 5, 10, 20, and 25 µM | Anti-proliferative | NA | [ |
(↑) increase, (↓) decrease, NA; not mentioned.
The molecular mechanisms of PCs and ACNs in combination with radiotherapy/chemotherapy in nicotine-induced NSCLC treatment.
| Study Type | NSCLC Cell Type | Extract/Compound | Concentrations | Activity | Mechanisms of Action | Reference |
|---|---|---|---|---|---|---|
| In vitro | A549 | Cinnamomi Cortex | 100–300 µg/mL | Anti-proliferative | Nrf2↓ | [ |
| In vitro/In vivo | A549 | Grape seed | 20 µg/mL (in vitro) | Anti-inflammation, apoptosis | ROS, IL-6, IFN-γ↓ | [ |
| In vitro | A549 | Delphinidin | 10, 20, and 50 µM | Apoptosis, autophagy | p-ERK1/2↓, | [ |
| In vitro | A549 | Cyanidin-3-glucoside | 1, 10, 20, and 50 µM | Apoptosis, autophagy | CLDN2, p-Akt↓, | [ |
(↑) increase; (↓) decrease.
Figure 2The therapeutic potential of PCs and ACNs in nicotine-induced NSCLC. (↓) decrease, (↑) increase.